Literature DB >> 16988102

Gene therapy for cancer treatment: past, present and future.

Deanna Cross1, James K Burmester.   

Abstract

The broad field of gene therapy promises a number of innovative treatments that are likely to become important in preventing deaths from cancer. In this review, we discuss the history, highlights and future of three different gene therapy treatment approaches: immunotherapy, oncolytic virotherapy and gene transfer. Immunotherapy uses genetically modified cells and viral particles to stimulate the immune system to destroy cancer cells. Recent clinical trials of second and third generation vaccines have shown encouraging results with a wide range of cancers, including lung cancer, pancreatic cancer, prostate cancer and malignant melanoma. Oncolytic virotherapy, which uses viral particles that replicate within the cancer cell to cause cell death, is an emerging treatment modality that shows great promise, particularly with metastatic cancers. Initial phase I trials for several vectors have generated excitement over the potential power of this technique. Gene transfer is a new treatment modality that introduces new genes into a cancerous cell or the surrounding tissue to cause cell death or slow the growth of the cancer. This treatment technique is very flexible, and a wide range of genes and vectors are being used in clinical trials with successful outcomes. As these therapies mature, they may be used alone or in combination with current treatments to help make cancer a manageable disease.

Entities:  

Mesh:

Year:  2006        PMID: 16988102      PMCID: PMC1570487          DOI: 10.3121/cmr.4.3.218

Source DB:  PubMed          Journal:  Clin Med Res        ISSN: 1539-4182


  65 in total

1.  Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model.

Authors:  P J Cozzi; S Malhotra; P McAuliffe; D A Kooby; H J Federoff; B Huryk; P Johnson; P T Scardino; W D Heston; Y Fong
Journal:  FASEB J       Date:  2001-05       Impact factor: 5.191

2.  Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses.

Authors:  J L Marshall; R J Hoyer; M A Toomey; K Faraguna; P Chang; E Richmond; J E Pedicano; E Gehan; R A Peck; P Arlen; K Y Tsang; J Schlom
Journal:  J Clin Oncol       Date:  2000-12-01       Impact factor: 44.544

3.  An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma.

Authors:  S S Yoon; H Nakamura; N M Carroll; B P Bode; E A Chiocca; K K Tanabe
Journal:  FASEB J       Date:  2000-02       Impact factor: 5.191

4.  Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.

Authors:  J Nemunaitis; I Ganly; F Khuri; J Arseneau; J Kuhn; T McCarty; S Landers; P Maples; L Romel; B Randlev; T Reid; S Kaye; D Kirn
Journal:  Cancer Res       Date:  2000-11-15       Impact factor: 12.701

5.  Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial.

Authors:  J M Markert; M D Medlock; S D Rabkin; G Y Gillespie; T Todo; W D Hunter; C A Palmer; F Feigenbaum; C Tornatore; F Tufaro; R L Martuza
Journal:  Gene Ther       Date:  2000-05       Impact factor: 5.250

6.  A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience).

Authors:  J P Lamont; J Nemunaitis; J A Kuhn; S A Landers; T M McCarty
Journal:  Ann Surg Oncol       Date:  2000-09       Impact factor: 5.344

7.  Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients.

Authors:  Alex W Tong; John Nemunaitis; Dan Su; Yuan Zhang; Casey Cunningham; Neil Senzer; George Netto; Dawn Rich; Abner Mhashilkar; Karen Parker; Keith Coffee; Rajagopal Ramesh; Suhendan Ekmekcioglu; Elizabeth A Grimm; Jill van Wart Hood; James Merritt; Sunil Chada
Journal:  Mol Ther       Date:  2005-01       Impact factor: 11.454

Review 8.  Clinical evaluation of adenoviral-mediated p53 gene transfer: review of INGN 201 studies.

Authors:  J A Merritt; J A Roth; C J Logothetis
Journal:  Semin Oncol       Date:  2001-10       Impact factor: 4.929

9.  The challenges of bringing autologous HSP-based vaccines to commercial reality.

Authors:  Neal F Gordon; Brian L Clark
Journal:  Methods       Date:  2004-01       Impact factor: 3.608

10.  Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses.

Authors:  P F McAuliffe; W R Jarnagin; P Johnson; K A Delman; H Federoff; Y Fong
Journal:  J Gastrointest Surg       Date:  2000 Nov-Dec       Impact factor: 3.267

View more
  78 in total

1.  The adeno-associated virus-mediated HSV-TK/GCV suicide system: a potential strategy for the treatment of bladder carcinoma.

Authors:  Jian Gang Pan; Xing Zhou; Runqi Luo; Rui Fa Han
Journal:  Med Oncol       Date:  2011-10-20       Impact factor: 3.064

Review 2.  Engineering Stem Cells for Biomedical Applications.

Authors:  Perry T Yin; Edward Han; Ki-Bum Lee
Journal:  Adv Healthc Mater       Date:  2015-03-13       Impact factor: 9.933

3.  Apoptosis prediction via inhibition of AKT signaling pathway by neogrifolin.

Authors:  Yang Chen; Guo-Fang Peng; Xiang-Zhen Han; Wei Wang; Guo-Qiang Zhang; Xiao Li
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

4.  Construction of artificial promoters sensitively responsive to sonication in vitro.

Authors:  Akihiko Watanabe; Satoshi Kakutani; Ryohei Ogawa; Sung-Il Lee; Toru Yoshida; Akihiro Morii; Go Kagiya; Loreto B Feril; Hideki Fuse; Takashi Kondo
Journal:  J Med Ultrason (2001)       Date:  2009-03-14       Impact factor: 1.314

Review 5.  Gene Delivery in Neuro-Oncology.

Authors:  Karan Dixit; Priya Kumthekar
Journal:  Curr Oncol Rep       Date:  2017-09-02       Impact factor: 5.075

6.  Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation.

Authors:  Samudra K Dissanayake; Purevdorj B Olkhanud; Michael P O'Connell; Arnell Carter; Amanda D French; Tura C Camilli; Chineye D Emeche; Kyle J Hewitt; Devin T Rosenthal; Poloko D Leotlela; Michael S Wade; Sherry W Yang; Larry Brant; Brian J Nickoloff; Jane L Messina; Arya Biragyn; Keith S Hoek; Dennis D Taub; Dan L Longo; Vernon K Sondak; Stephen M Hewitt; Ashani T Weeraratna
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

7.  Advances in the mechanisms of action of cancer-targeting oncolytic viruses.

Authors:  Cun-Zhi Lin; Gui-Ling Xiang; Xin-Hong Zhu; Lu-Lu Xiu; Jia-Xing Sun; Xiao-Yuan Zhang
Journal:  Oncol Lett       Date:  2018-01-19       Impact factor: 2.967

8.  rAAV9-UPII-TK-EGFP can precisely transduce a suicide gene and inhibit the growth of bladder tumors.

Authors:  Foyan Lian; Qiang Ye; Bing Feng; Hui Cheng; Shaomin Niu; Ning Fan; Degui Wang; Zhiping Wang
Journal:  Cancer Biol Ther       Date:  2020-11-20       Impact factor: 4.742

Review 9.  The history of tumor virology.

Authors:  Ronald T Javier; Janet S Butel
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

10.  Immune-mediated anti-neoplastic effect of intratumoral RSV envelope glycoprotein expression is related to apoptotic death of tumor cells but not to the size of syncytia.

Authors:  Dennis Hoffmann; Thomas Grunwald; Wibke Bayer; Oliver Wildner
Journal:  World J Gastroenterol       Date:  2008-03-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.